SecBot SecBot

CELZ

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. NV· CIK 0001187953 Biotech & Drug Discovery
$0.7120 −0.03 (−3.78%)
Oct 26 4:00 PM ET · prev $0.7400
Market cap
$5.9M
Nano cap
Median target
$20.00
+2709% · range $20.00–20.00
Next earnings
Nov 5
in 9 days · EPS est. −$0.24
1 year
−86.2%
from $5.14 · Oct 27
30 days
−29.5%
from $1.01
52-week range
$0.6542–5.59
−87% from high · low Aug 3
Avg volume 20D
111.3K
Oct 20 spike 404.9K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 5, 2026
Strongest MIXED Creative Medical Technology Holdings (CELZ) acquired an additional 4 million shares of BioDefense, Inc. from…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.230 → −$0.240 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    26% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM25,799$37.4K
UBS Group AGDOUBLED2,061$3.0K
GEODE CAPITAL MANAGEMENT, LLCADD38,290$78.9K
MORGAN STANLEYDOUBLED534$1.1K
UBS Group AGNEAR_EXIT1$2.00
BANK OF AMERICA CORP /DE/DOUBLED5,132$10.1K
UBS Group AGDOUBLED11$22.00
VANGUARD GROUP INCADD25,868$85.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12-month targets · 1 analysts

Price is below the lowest target. Median implies +2709%.Targets as of Oct 27, 2026.

Insider ledger

Form 4
🔒 Subscribers only
1 transactions
DateInsiderTypeValue
Sep 24, 2026🔒 Fresh data, subscribers onlyAWARD

Earnings setup

Estimates
Nov 5
reports in 9 days
−$0.24
EPS estimate, this quarter
−4%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.24-$0.24–-$0.24+0.0%$0.00
Next Q-$0.24-$0.24–-$0.24+0.0%$0.00
Current FY-$1.18-$1.18–-$1.18+0.0%$0.00
Next FY-$0.88-$0.88–-$0.88+0.0%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
CELZ Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Oct 25, 2026
Trial readout
T-90d Trial Readout: CELZ-201-DDT (Phase 2)
Trial: Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain Sponsor…
Oct 21, 2026
Trial readout
T-90d Trial Readout: CELZ-201-DDT (Phase 2)
Trial: Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain Sponsor…
Oct 20, 2026
Press release
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free...
Sep 17, 2026
FDA
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
New Filing Seeks Broad Protection Around Creative Medical’s Cell-Free Regenerative Platform, Including Product Composition, Functional Potency…
Aug 31, 2026
Reg SHO list
Reg SHO Threshold: CELZ exited the threshold list
CREATIVE MED TECHNOLOGY HLDGS | On list since 2026-08-12

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 6, 2026Volatility PauseResumed
Aug 6, 2026Volatility PauseResumed
Aug 6, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 25, 2026 Clinical trial readout
T-90d Trial Readout: CELZ-201-DDT (Phase 2)
Trial: Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Tr
Oct 1, 2026 SEC
CEO Timothy Warbington and his entity Creative Acquisition Corp. filed a Schedule 13D disclosing beneficial ownership…
SC 13D — Impact 4/10
Sep 25, 2026 SEC
Creative Medical Technology Holdings (CELZ) acquired an additional 4 million shares of BioDefense, Inc. from affiliate…
8-K — Impact 5/10
Sep 24, 2026 Insider
🔒 Fresh data, subscribers only
Sep 17, 2026 Press
Creative Medical Technology Holdings filed a provisional patent application covering its Ultrasome cell-free…
Impact 2/10
Aug 20, 2026 Press
Creative Medical Technology announced that all patients have been enrolled and treated across its ADAPT clinical trial…
Impact 5/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
25,799 shares ($37.4K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
2,061 shares ($3.0K)

SecBot reports

4 filings · 5 press releases · 0 bullish · 1 bearish · 1 mixed · 2 neutral
All CELZ filing & press-release reports (9)